Metastatic colorectal adenocarcinoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)The subject has histologically confirmed colorectal adenocarcinoma. 2)The subject has metastatic or locally advanced disease not amendable to curative surgery. 3)The subject must be currently receiving or prior to first-line chemotherapy. 4)The subject is at least 20 years of age at the time of informed consent. 5)The patient has provided singed informed consent prior to any study specific procedures.
Exclusion criteria
Exclusion criteria: 1)The subject has other malignancies which affect the patients' survival time. 2)The tumor has previously confirmed RAS mutant or BRAF mutant colorectal cancer. 3)The subject is receiving or panning to concomitant radiotherapy for primary site. 4)The subject is not appropriate for this study due to any other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe frequency of BRAF mutations (V600E and non-V600E mutations) in KRAS/NRAS wild-type metastatic colorectal adenocarcinoma. | — |
Countries
Japan
Contacts
Aichi Cancer Center Hospital Department of Clinical Oncology